Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorAin Shams University
About this trial
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Eligibility criteria
Qualifiers
Age ≥ 18 years and ≤ 65 years
Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
Any stage of disease (nodal or extra-nodal), with or without B symptoms
Scheduled to receive standard systemic treatment (R-CHOP)
Disqualifiers
History of other concurrent or previous malignancies
Relapsed or refractory DLBCL
Diabetes mellitus
Autoimmune diseases
Trial design
Treatments tested in this trial
- Observational Assessment of Standard R-CHOP Treatment
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov